RIGL
RIGEL PHARMACEUTICALS INC
$30.72
-0.02%
$568.4M
No data for this timeframe.
Vol
Market Cap$568.4M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders8 funds
Inst. Value$103.2M
Inst. Activity1 buys / 0 sells
Insider Activity0B / 1S
Insider Net $-$72.9K
SEC Reports5
Recent Activity
Jun 1, 2026
Insider
Schorno Dean L sold 1,200 shares
EVP & Chief Financial Officer @ $18.70 ($22.4K)
Jun 1, 2026
Insider
Furey Raymond J. sold 877 shares
EVP, GC, CCO & Corp Sec @ $29.86 ($26.2K)
Jun 1, 2026
Insider
Schorno Dean L sold 1,200 shares
EVP & Chief Financial Officer @ $0.00 ($0.00)
May 20, 2026
SEC
Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders approv
8-K — Impact 2/10
May 12, 2026
SEC
Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer for VEPPANUTM (vepdeg
8-K — Impact 7/10
May 5, 2026
SEC
Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY r
8-K — Impact 7/10
Inst.
BANK OF AMERICA CORP — ADD
116,952 shares ($5.0M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
474,209 shares ($13.4M)
Price Targets
$53.20
+73.2% upside
Strong Buy
Current $30.72
Low $38.00
Median $50.00
High $81.00
5 analysts
$38.00
$81.00
Analyst Ratings
4Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 13, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| May 7, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.06 ▼ -93.9% | $-2.66 — $1.11 | -98% YoY | 4 |
| Next Q | $1.27 ▲ +5.3% | $1.15 — $1.62 | -13% YoY | 4 |
| Current FY | $3.09 ▼ -35.7% | $0.64 — $4.01 | -52% YoY | 4 |
| Next FY | $4.58 ▼ -4.5% | $2.83 — $8.57 | 48% YoY | 4 |
Latest Reports
NEUTRAL
8-K
2/10
Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders approv
May 20, 2026
BULLISH
8-K
7/10
Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer for VEPPANUTM (vepdeg
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $44.5M | — |
| RENAISSANCE TECHNOLOGIES LLC | $23.1M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $11.6M | DOUBLED |
| MORGAN STANLEY | $7.1M | NEAR_EXIT |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $6.4M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Schorno Dean | M | $22.4K |
| Jun 1, 2026 | Furey Raymond | F | $26.2K |
| Jun 1, 2026 | Schorno Dean | M | $0.00 |
| Jun 1, 2026 | Schorno Dean | F | $27.7K |
| Jun 1, 2026 | Rojkjaer Lisa | F | $25.4K |
8 institutional holders with $103.2M total value (2,410,559 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,038,408 | $44.5M | 43.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 539,009 | $23.1M | 22.4% | DOUBLED +100.6% |
| 3 | TWO SIGMA INVESTMENTS, LP | 271,228 | $11.6M | 11.3% | DOUBLED +474.6% |
| 4 | MORGAN STANLEY | 166,489 | $7.1M | 6.9% | NEAR_EXIT -90.4% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 148,636 | $6.4M | 6.2% | DOUBLED +132.0% |
| 6 | BANK OF AMERICA CORP /DE/ | 116,952 | $5.0M | 4.9% | ADD +55.0% |
| 7 | FMR LLC | 67,838 | $2.9M | 2.8% | DOUBLED +1641.4% |
| 8 | WELLS FARGO & COMPANY/MN | 61,999 | $2.7M | 2.6% | TRIM -38.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 75,476 | 116,952 | +55.0% | $5.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 236,446 | 474,209 | +100.6% | $13.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 38,342 | 220,298 | +474.6% | $6.2M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 77,491 | 179,808 | +132.0% | $5.1M | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 1,520,217 | 146,266 | -90.4% | $4.1M | 2025-Q3 |
| UBS Group AG | ADD | 68,056 | 100,597 | +47.8% | $2.8M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 187,621 | 75,476 | -59.8% | $2.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 98,844 | 60,828 | -38.5% | $1.7M | 2025-Q3 |
| FMR LLC | DOUBLED | 3,393 | 59,087 | +1641.4% | $1.7M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 132,437 | 187,621 | +41.7% | $3.5M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 8,798 | 98,844 | +1023.5% | $1.9M | 2025-Q2 |
| UBS Group AG | ADD | 46,715 | 68,056 | +45.7% | $1.3M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 12,678 | 38,342 | +202.4% | $718.1K | 2025-Q2 |
| FMR LLC | TRIM | 10,612 | 3,393 | -68.0% | $63.6K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 299,709 | 201,146 | -32.9% | $3.6M | 2025-Q1 |
| UBS Group AG | DOUBLED | 13,667 | 46,715 | +241.8% | $840.4K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 50,411 | 23,600 | -53.2% | $424.6K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 60,913 | 12,678 | -79.2% | $228.1K | 2025-Q1 |
| NORGES BANK | EXIT | 129,506 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 141,946 | 299,709 | +111.1% | $5.0M | 2024-Q4 |
| NORGES BANK | NEW | — | 129,506 | — | $2.2M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 19,430 | 50,411 | +159.4% | $847.9K | 2024-Q4 |
| UBS Group AG | ADD | 9,176 | 13,667 | +48.9% | $229.9K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 5,955 | 8,603 | +44.5% | $144.7K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 77,407 | — | $1.3M | 2024-Q3 |
12 unique insiders with 1 transactions. Net insider value: -$72.9K ($0.00 bought, $72.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Schorno Dean L | EVP & Chief Financial Officer | M | 1,200 | $18.70 | $22.4K |
| Jun 1, 2026 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | F | 877 | $29.86 | $26.2K |
| Jun 1, 2026 | Schorno Dean L | EVP & Chief Financial Officer | M | 1,200 | $0.00 | $0.00 |
| Jun 1, 2026 | Schorno Dean L | EVP & Chief Financial Officer | F | 928 | $29.86 | $27.7K |
| Jun 1, 2026 | Rojkjaer Lisa | EVP, Chief Medical Officer | F | 850 | $29.86 | $25.4K |
| Jun 1, 2026 | Santos David A | EVP, Chief Commercial Officer | F | 874 | $29.86 | $26.1K |
| Jun 1, 2026 | RODRIGUEZ RAUL R | CEO, President | F | 2,424 | $29.86 | $72.4K |
| May 26, 2026 | Ali-Jackson Kamil | Director | SELL | 2,500 | $29.17 | $72.9K |
| May 15, 2026 | MOOS WALTER H | Director | A | 5,750 | $0.00 | $0.00 |
| May 15, 2026 | Ali-Jackson Kamil | Director | A | 5,750 | $0.00 | $0.00 |
| May 15, 2026 | Frohlich Mark W | Director | A | 5,750 | $0.00 | $0.00 |
| May 15, 2026 | HANNAH ALISON L. | Director | A | 5,750 | $0.00 | $0.00 |
| May 15, 2026 | LAPOINTE ANTHONY GREGG | Director | A | 5,750 | $0.00 | $0.00 |
| May 15, 2026 | MILLER MICHAEL PATRICK | Director | A | 5,750 | $0.00 | $0.00 |
| May 15, 2026 | Wasman Jane | Director | A | 5,750 | $0.00 | $0.00 |
| Feb 20, 2026 | MOOS WALTER H | Director | M | 4,000 | $24.00 | $96.0K |
| Feb 20, 2026 | MOOS WALTER H | Director | M | 4,000 | $0.00 | $0.00 |
| Feb 10, 2026 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | F | 3,546 | $34.62 | $122.8K |
| Feb 10, 2026 | Santos David A | EVP, Chief Commercial Officer | F | 3,546 | $34.62 | $122.8K |
| Feb 10, 2026 | Rojkjaer Lisa | EVP, Chief Medical Officer | F | 3,758 | $34.62 | $130.1K |
| Feb 10, 2026 | Schorno Dean L | EVP & Chief Financial Officer | F | 3,546 | $34.62 | $122.8K |
| Feb 10, 2026 | RODRIGUEZ RAUL R | CEO, President | F | 7,607 | $34.62 | $263.4K |
| Feb 2, 2026 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | F | 3,968 | $36.01 | $142.9K |
| Feb 2, 2026 | Santos David A | EVP, Chief Commercial Officer | F | 5,718 | $36.01 | $205.9K |
| Feb 2, 2026 | Schorno Dean L | EVP & Chief Financial Officer | F | 5,488 | $36.01 | $197.6K |
| Feb 2, 2026 | RODRIGUEZ RAUL R | CEO, President | F | 14,110 | $36.01 | $508.1K |
| Feb 1, 2026 | MILLER MICHAEL PATRICK | Director | A | 12,000 | $0.00 | $0.00 |
| Jan 26, 2026 | RODRIGUEZ RAUL R | CEO, President | M | 40,000 | $27.40 | $1.1M |
| Jan 26, 2026 | RODRIGUEZ RAUL R | CEO, President | F | 35,211 | $37.00 | $1.3M |
| Jan 26, 2026 | RODRIGUEZ RAUL R | CEO, President | M | 40,000 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
NEUTRAL
8-K
2/10
Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders.
May 20, 2026
BULLISH
8-K
7/10
Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer f
May 12, 2026
BEARISH
8-K
7/10
Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5
May 5, 2026
BEARISH
8-K
7/10
Rigel Pharmaceuticals announced that Eli Lilly has elected to terminate their 2021 License and Colla
Apr 21, 2026
NEUTRAL
DEFA14A
2/10
RIGEL PHARMACEUTICALS INC filed a Definitive Additional Materials (DEFA14A) form, which is supplemen
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (73% buy). Based on 11 analysts: 4 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$53.20 mean target
+73.2% upside
Strong Buy (1.80)
$38.00 Low
$81.00 High
| Metric | Value |
|---|---|
| Current Price | $30.72 |
| Target Low | $38.00 |
| Target Mean | $53.20 |
| Target Median | $50.00 |
| Target High | $81.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.80) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.06 | $-2.66 | $1.11 | -98.0% | -93.9% | 0↑ 1↓ | $0.1B | -46.0% | 4 |
| Next Q 2026-09-30 |
$1.27 | $1.15 | $1.62 | -12.7% | +5.3% | 0↑ 1↓ | $0.1B | 10.3% | 4 |
| Current FY 2026-12-31 |
$3.09 | $0.64 | $4.01 | -52.0% | -35.7% | 0↑ 3↓ | $0.3B | -8.3% | 4 |
| Next FY 2027-12-31 |
$4.58 | $2.83 | $8.57 | 48.4% | -4.5% | 2↑ 1↓ | $0.3B | 22.2% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.065 | |
| 7d ago | $0.065 | |
| 30d ago | $1.065 | -1.000 |
| 60d ago | $1.065 | -1.000 |
| 90d ago | $1.070 | -1.005 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 13, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 7, 2026 | Citigroup | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% | |
| Apr 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% | |
| Mar 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% | |
| Feb 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% | |
| Jan 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 5, 2026
earnings_calendar
RIGL Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
earnings_calendar
RIGL Q1 2026 Earnings Scheduled — 2026-05-04
Mar 2, 2026
earnings_calendar
RIGL Q4 2025 Earnings After Market Close — 2026-03-02
Feb 9, 2026
short_interest
FTD: RIGL — 28,989 shares ($1.0M) failed to deliver
Settlement: 20260209, Price: $34.15, FTD Value: $989,974.35, RIGEL PHARMACEUTICALS INC COM